Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 13/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 13/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 13/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7691375 | 0.85 | OPRL1 (0.60) | OPRM1OPRK1OPRL1OPRD1CYP3A4 | |
| SCHEMBL21639941 | 0.82 | OPRL1 (0.74) | OPRM1OPRK1OPRL1OPRD1CYP3A4 | |
| SCHEMBL2142315 | 0.81 | OPRM1 (0.51) | OPRM1OPRK1OPRL1OPRD1CYP3A4 | |
| SCHEMBL13317173 | 0.81 | OPRM1 (0.51) | OPRM1OPRK1OPRL1OPRD1CYP3A4 | |
| SCHEMBL69083 | 0.81 | OPRM1 (0.56) | OPRM1OPRK1OPRL1OPRD1CYP3A4 | |
| SCHEMBL21590633 | 0.80 | OPRM1 (0.49) | OPRM1OPRK1OPRL1OPRD1CYP3A4 | |
| SCHEMBL1742229 | 0.79 | OPRM1 (0.71) | OPRM1OPRK1OPRL1OPRD1CYP3A4 | |
| SCHEMBL4578709 | 0.78 | CYP3A4 (0.49) | OPRM1OPRK1OPRL1OPRD1CYP3A4 | |
| SCHEMBL3224569 | 0.77 | OPRM1 (0.48) | OPRM1OPRK1OPRL1OPRD1CYP3A4 | |
| SCHEMBL18785421 | 0.74 | OPRM1 (0.49) | OPRM1OPRK1OPRL1OPRD1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250100966-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | EXELIXIS INC (US) | 2025-03-27 | — | — | US | disclosed |
| US-11597699-B2 | MEK inhibitors and methods of their use | EXELIXIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| CN-109053523-B | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 埃克塞利希斯股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-111643496-A | Methods of using MEK inhibitors | 埃克塞利希斯股份有限公司 | 2020-09-11 | — | — | CN | disclosed |
| US-20200283383-A1 | MEK Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2020-09-10 | — | — | US | disclosed |
| US-20200031770-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | EXELIXIS, INC. | 2020-01-30 | — | — | US | disclosed |
| CN-110668988-A | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 埃克塞利希斯股份有限公司 | 2020-01-10 | — | — | CN | disclosed |
| US-20190144382-A1 | MEK Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2019-05-16 | — | — | US | disclosed |
| EP-2101759-B1 | METHODS OF USING MEK INHIBITORS | EXELIXIS INC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20170166523-A9 | MEK Inhibitors And Methods Of Their Use | EXELIXIS, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20100249096-A1 | anticarcinogenic agent; 1-({4-[(2-fluoro-4-iodophenyl)amino]-3-thienyl}carbonyl)azetidin-3-amine | EXELIXIS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7803839-B2 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | EXELIXIS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| EP-2101759-A1 | METHODS OF USING MEK INHIBITORS | Exelixis, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| US-20090156576-A1 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | EXELIXIS INC. (US) | 2009-06-18 | — | — | US | disclosed |
| CN-101365676-A | Azetidines as mek inhibitors for the treatment of proliferative diseases | EXELIXIS INC (US) | 2009-02-11 | — | — | CN | disclosed |
| WO-2008124085-A2 | METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | disclosed |
| WO-2008076415-A1 | METHODS OF USING MEK INHIBITORS | EXELIXIS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| EP-1934174-A1 | AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007044515-A1 | AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166523-A9 | MEK Inhibitors And Methods Of Their Use | BRAF, NRAS, MAP3K1 | OPRM1 2892/4885OPRK1 1390/4885OPRL1 3259/4885 |
| US-20200283383-A1 | MEK Inhibitors and Methods of Their Use | BRAF, NRAS, MAP3K20 | OPRM1 2870/4885OPRK1 1385/4885OPRL1 3150/4885 |
| US-20100249096-A1 | anticarcinogenic agent; 1-({4-[(2-fluoro-4-iodophenyl)amino]-3-thienyl}carbonyl)azetidin-3-amine | NRAS, BRAF, KRAS | OPRM1 2706/4885OPRK1 1840/4885OPRL1 3808/4885 |
| US-20090156576-A1 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | NRAS, BRAF, KRAS | OPRM1 2839/4885OPRK1 1637/4885OPRL1 3654/4885 |
| US-20250100966-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | BRAF, NRAS, KRAS | OPRM1 2352/4885OPRK1 1239/4885OPRL1 3031/4885 |
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | OPRM1 3810/4885OPRK1 2511/4885OPRL1 3548/4885 |
| US-20190144382-A1 | MEK Inhibitors and Methods of Their Use | BRAF, NRAS, MAP3K20 | OPRM1 2870/4885OPRK1 1385/4885OPRL1 3150/4885 |
| US-11597699-B2 | MEK inhibitors and methods of their use | BRAF, NRAS, MAP3K20 | OPRM1 2870/4885OPRK1 1385/4885OPRL1 3150/4885 |
| US-20200031770-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | BRAF, NRAS, MAP3K20 | OPRM1 2870/4885OPRK1 1385/4885OPRL1 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.